Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, ...
The American College of Cardiology (ACC) and the American Heart Association (AHA) issued new scientific statements advocating use of quantified coronary plaque analyses in management of patients with ...
Eilean Therapeutics LLC has announced it is advancing ZE74-0282 into first-in-human development, with the submission of an IND application and enrollment planned to begin in the first quarter of next ...
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...
Med-tech M&A value in 2025 totaled about $38.99 billion through November, reflecting a clear slowdown from 2024’s $57.92 billion and well below the peak years of 2021 and 2022, when 11-month totals ...
Biopharma happenings, including deals and partnerships, and other news in brief: Alnylam, Astrazeneca, Caris, Compugen, Eli Lilly, Medi&Gene, Norgine, Protalix, Roche, Secarna, Vir, Vyne, Yarrow.
The BioWorld Biopharmaceutical Index extended its autumn rally after a more modest September, finishing November up 23.41% for the year. The gain lagged the Nasdaq Biotechnology Index, which surged 34 ...
The FDA’s final guidance for the use of real-world evidence (RWE) was touted by FDA commissioner Marty Makary as opening the door to the use of existing de-identified data in premarket device ...
Eli Lilly and Co. disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist. The compound was tested for ...
Co. Ltd. has synthesized cyclosporin derivatives acting as peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF; cyclophilin D) and/or peptidyl-prolyl cis-trans isomerase A (PPIA; cyclophilin A; ...
Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that ...
Rznomics Inc. continued South Korea’s year-end biotech rally with a ₩46.35 billion (US$31.35 million) IPO Dec. 18. Proceeds will fund Seongnam-si, South Korea-based Rznomic’s pipeline of gene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback